Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193999 | 0.69 | PGR (0.44) | SLC6A4HTR2AHTR2C | |
| SCHEMBL18474170 | 0.68 | KMT2A (0.34) | — | |
| SCHEMBL18469608 | 0.64 | SLC6A4 (0.35) | SLC6A4HTR2AHTR2C | |
| SCHEMBL26077198 | 0.64 | CA1 (0.38) | SLC6A4HTR2AHTR2C | |
| SCHEMBL26077196 | 0.63 | CA1 (0.37) | SLC6A4HTR2AHTR2C | |
| SCHEMBL12964403 | 0.61 | AVPR1A (0.43) | — | |
| SCHEMBL18474236 | 0.61 | PGR (0.45) | — | |
| SCHEMBL6654384 | 0.61 | SLC6A4 (0.58) | SLC6A4HTR2AHTR2C | |
| SCHEMBL30574141 | 0.59 | AVPR1A (0.41) | SLC6A4 | |
| SCHEMBL11827622 | 0.59 | AVPR1A (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | HTR1D 52/4885HTR1B 34/4885SLC6A4 410/4885 |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | HTR1D 52/4885HTR1B 34/4885SLC6A4 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.